FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan for Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to izalontamab brengitecan (Iza-bren), an investigational treatment for adults with advanced non-small cell lung cancer (NSCLC).
The designation applies to patients whose tumors carry EGFR exon 19 deletions or exon 21 L858R mutations and who have already progressed after receiving both an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
Iza-bren introduces a novel therapeutic strategy as a bispecific antibody–drug conjugate that binds to EGFR and HER3 simultaneously while delivering a topoisomerase I inhibitor payload directly to tumor cells.
The therapy was initially developed by Biokin in China and is now being advanced worldwide through a partnership between SystImmune and Bristol Myers Squibb.
For people living with EGFR-mutant NSCLC, resistance to TKI therapy almost always develops, leaving chemotherapy as the main fallback—an approach that can offer limited benefit and difficult side effects.
By granting Breakthrough Therapy Designation, the FDA is signaling that izalontamab brengitecan has the potential to significantly improve on available treatments.
The decision is supported by promising results from three ongoing clinical studies: BL-B01D1-101 and BL-B01D1-203 in China, along with the global BL-B01D1-LUNG-101 trial across the U.S., Europe, and Japan.
Early findings suggest that Iza-bren demonstrates encouraging clinical activity and a manageable safety profile in patients who have already exhausted targeted therapies and chemotherapy.
This marks the first time izalontamab brengitecan has received Breakthrough Therapy Designation in the United States, setting the stage for accelerated development and review as it moves closer to becoming a potential new option for patients with advanced EGFR-driven lung cancer.
